Meningococcal Group B Vaccine

BreastfeedingGeriatricPediatric
  • TRADE NAMES: Bexsero (Novartis); Trumenba (Wyeth)
  • INDICATIONS: Immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B
  • CLASS: Vaccine
  • HALF-LIFE: N/A

FDA APPROVAL DATE: 10/29/2014

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: B

Our database has 16 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
LOCAL
OTHER


Page last updated 01/17/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric